Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Complix Appoints Dr Yvonne McGrath as CSO

Published: Saturday, May 17, 2014
Last Updated: Saturday, May 17, 2014
Bookmark and Share
Dr McGrath will be responsible for the use of the Company´s Alphabody platform.

Complix has announced that it has appointed Yvonne McGrath as Chief Scientific Officer (CSO).

As CSO of Complix, Dr McGrath will be responsible for the use of the Company´s Alphabody platform to identify new drug candidates and take these forward into development, either internally or with partners.

This is part of Complix´ wider goal to build a pipeline of transformative Alphabody protein therapeutics. Dr Ignace Lasters, previously CSO and co-founder of Complix, will assume the role of Chief Technology Officer (CTO), and will be responsible for the further development and expansion of the Alphabody technology platform.

Dr McGrath was most recently at Immunocore as Head of Development and before that as Head of Preclinical Development and CMC. In these positions, she successfully developed and executed the late preclinical and early clinical strategy for a novel platform technology, managed meetings with European and US regulatory authorities and led manufacturing and CMC strategy for a new biological entity targeting cancer.

Dr McGrath’s previous experience includes being a Project Manager at the UK subsidiary of the German biotech company MediGene AG, and Senior Scientist at BioVex (now part of Amgen). She has a PhD from the University of Wales, College of Medicine.

Dr Mark Vaeck, CEO of Complix, said: “I am delighted to welcome Yvonne to strengthen our management team, as we enter an exciting phase in Complix’ development. We are continuing to generate promising data with our lead oncology anti-MCL-1 program, which has shown that CPABs can exert potent activity against an important intracellular cancer target. Yvonne’s expertise in the preclinical and early clinical development of novel platform technologies will be a great asset to the Company as we seek to expand and accelerate our CPAB programs.”

Dr McGrath, commenting on her appointment, said: “I have been very impressed with the potential of Complix’ unique Alphabody platform. CPABs clearly have the potential to transform drug development by being able to reach a range of important intracellular disease targets which are known but cannot be addressed with existing protein therapeutics. I am excited to be a key member of the Complix team and look forward to taking a number of CPABs into the clinic.”

It is estimated that there are more than 1000 intracellular disease targets which are known to be involved in important disease processes, but are currently undruggable by conventional therapeutics. Complix’ CPABs have the unique capacity to enter cells effectively and modulate intracellular protein-to-protein interactions (PPIs).

The Company has generated compelling data with its lead program against the intracellular cancer target MCL-1. MCL-1 is an important regulator of cellular apoptosis and is often over-expressed in cancer cells thereby preventing them from dying.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Complix Launches Strategic Collaboration with Merck
Complix to receive upfront fees, research funding, and milestone payments.
Thursday, January 07, 2016
Complix Raises €12 Million (US$15.5 million) in Series B Round
Financing to advance Alphabodies™, a unique class of protein therapeutics active against intracellular disease targets.
Wednesday, June 26, 2013
Complix Receives €1.9 Million IWT Grant
Grant to accelerate development of Alphabodies™ against intracellular disease targets, including cancer.
Tuesday, October 30, 2012
Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!